ATE426402T1 - Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l - Google Patents

Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l

Info

Publication number: ATE426402T1
Authority: AT; Austria
Prior art keywords: octylphenyl; amino; ethylupropane; compositions containing; medical compositions
Prior art date: 1998-01-19

Application number

AT99900351T

Other languages

English (en)

Inventor

Atsushi Sakai

Rumiko Masuda

Tsuneo Fujii

Tadashi Mishina

Kenji Chiba

Original Assignee

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-19

Filing date

1999-01-19

Publication date

2009-04-15

1999-01-19 Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE426402T1 publication Critical patent/ATE426402T1/de

Links

239000000203 mixture Substances 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
229920000858 Cyclodextrin Polymers 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
238000010322 bone marrow transplantation Methods 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Nanotechnology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Rheumatology (AREA)
Crystallography & Structural Chemistry (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Transplantation (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99900351T 1998-01-19 1999-01-19 Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l ATE426402T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP10008045A JPH11209277A (ja)	1998-01-19	1998-01-19	医薬組成物

Publications (1)

Publication Number	Publication Date
ATE426402T1 true ATE426402T1 (de)	2009-04-15

Family

ID=11682381

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99900351T ATE426402T1 (de)	1998-01-19	1999-01-19	Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l

Country Status (15)

Country	Link
EP (1)	EP1050301B1 (de)
JP (2)	JPH11209277A (de)
KR (1)	KR100546450B1 (de)
CN (1)	CN1191062C (de)
AT (1)	ATE426402T1 (de)
AU (1)	AU1891199A (de)
BR (1)	BR9907099A (de)
CA (1)	CA2319217C (de)
DE (1)	DE69940633D1 (de)
ES (1)	ES2323199T3 (de)
IL (1)	IL137362A (de)
NZ (1)	NZ506408A (de)
PT (1)	PT1050301E (de)
RU (1)	RU2204387C2 (de)
WO (1)	WO1999036065A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4627356B2 (ja) *	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
EP1315735A4 (de)	2000-08-31	2005-04-06	Merck & Co Inc	Phosphat-derivate als immunoregulatorische verbindungen
JP2007217438A (ja) *	2001-07-17	2007-08-30	Shionogi & Co Ltd	注射用医薬製剤
TWI232102B (en) *	2001-07-17	2005-05-11	Shionogi & Co	A pharmaceutical formulation for injection
GB0125443D0 (en)	2001-10-23	2001-12-12	Novartis Ag	Organic Compounds
DK1471054T3 (da)	2002-01-11	2009-11-09	Daiichi Sankyo Co Ltd	Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
AU2003233119A1 (en)	2002-05-08	2003-11-11	Neuronova Ab	Modulation of neural stem cells with s1p or lpa receptor agonists
PE20130200A1 (es) *	2003-04-08	2013-03-09	Novartis Ag	Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
EP1484057A1 (de) *	2003-06-06	2004-12-08	Aventis Pharma Deutschland GmbH	Verwendung von 2-amino-1,3-propandiolderivaten zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen
US7524887B2 (en)	2003-06-06	2009-04-28	Sanofi-Aventis Deutschland Gmbh	2-amino-1,3-propanediol compounds for the treatment of acute pain
NZ549162A (en)	2004-02-24	2009-12-24	Sankyo Co	Amino-pyrrol alcohol compounds
PL1773307T3 (pl) *	2004-07-30	2015-03-31	Novartis Ag	Preparaty 2-amino-1,3-propanodioli i ich analogów
PL2278960T5 (pl) *	2008-03-17	2020-06-29	Actelion Pharmaceuticals Ltd.	Schemat dawkowania dla selektywnego agonisty receptora sip1
WO2011009634A2 (en) *	2009-07-24	2011-01-27	Ratiopharm Gmbh	Process for producing fingolimod salts
AR085749A1 (es) *	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
DE102012101680A1 (de) *	2012-02-29	2013-08-29	Aicuris Gmbh & Co. Kg	Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
AU2019228913C1 (en) *	2018-03-01	2024-10-31	Ishihara Sangyo Kaisha, Ltd.	Pharmaceutical composition with excellent storage stability

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS51133960A (en) *	1975-05-16	1976-11-20	Kao Corp	Defoaming method
JPS5718607A (en) *	1980-07-07	1982-01-30	Kaken Pharmaceut Co Ltd	Injection preparation
JPS58148816A (ja) *	1982-02-27	1983-09-05	Nippon Zenyaku Kogyo Kk	低刺激性チアムリン注射剤
JPS63253022A (ja) *	1987-04-08	1988-10-20	Nitto Electric Ind Co Ltd	バクロフエン外用製剤
DE68906942T3 (de) *	1988-03-29	1999-05-12	University Of Florida, Gainesville, Fla.	Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
IE62095B1 (en) *	1988-03-29	1994-12-14	Univ Florida	Pharmaceutical formulations for parenteral use
JP3054776B2 (ja) *	1990-04-13	2000-06-19	丸善製薬株式会社	グリチルリチンの甘味抑制方法
TW200402B (de) *	1990-08-13	1993-02-21	Senju Pharma Co
JPH0616547A (ja) *	1992-07-01	1994-01-25	Wakamoto Pharmaceut Co Ltd	消炎点眼剤
DE69321823T2 (de) *	1992-10-21	1999-06-02	Taito Co., Ltd., Tokio/Tokyo	2-amino-1, 3- propandiolverbindung und immunosuppressium
JP2879395B2 (ja) *	1992-10-26	1999-04-05	富士写真フイルム株式会社	ロダシアニン化合物及びシクロデキストリンを含有する抗癌性組成物
JPH07228532A (ja) *	1993-04-22	1995-08-29	Senju Pharmaceut Co Ltd	水性液剤、その有効成分の溶解性向上方法および安定化方法
JPH07316065A (ja) *	1994-05-25	1995-12-05	Fujisawa Pharmaceut Co Ltd	Ｆｒ９０１４６９物質製剤
EP0778263B1 (de) *	1994-08-22	2002-01-09	Welfide Corporation	Benzolderivate und deren medizinische verwendung
JPH0859483A (ja) *	1994-08-25	1996-03-05	Higeta Shoyu Co Ltd	抗真菌製剤
JPH08175985A (ja) *	1994-12-26	1996-07-09	Lion Corp	点眼剤
WO1997024112A1 (en) *	1995-12-28	1997-07-10	Yoshitomi Pharmaceutical Industries, Ltd.	External preparation
JP2002241272A (ja) *	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物

1998
- 1998-01-19 JP JP10008045A patent/JPH11209277A/ja active Pending
1999
- 1999-01-19 BR BR9907099-5A patent/BR9907099A/pt not_active Application Discontinuation
- 1999-01-19 CN CNB998041645A patent/CN1191062C/zh not_active Expired - Fee Related
- 1999-01-19 NZ NZ506408A patent/NZ506408A/xx unknown
- 1999-01-19 AU AU18911/99A patent/AU1891199A/en not_active Abandoned
- 1999-01-19 JP JP2000539838A patent/JP4434486B2/ja not_active Expired - Lifetime
- 1999-01-19 CA CA002319217A patent/CA2319217C/en not_active Expired - Fee Related
- 1999-01-19 PT PT99900351T patent/PT1050301E/pt unknown
- 1999-01-19 WO PCT/JP1999/000152 patent/WO1999036065A1/ja not_active Ceased
- 1999-01-19 AT AT99900351T patent/ATE426402T1/de active
- 1999-01-19 IL IL13736299A patent/IL137362A/xx not_active IP Right Cessation
- 1999-01-19 KR KR1020007007911A patent/KR100546450B1/ko not_active Expired - Fee Related
- 1999-01-19 DE DE69940633T patent/DE69940633D1/de not_active Expired - Lifetime
- 1999-01-19 EP EP99900351A patent/EP1050301B1/de not_active Expired - Lifetime
- 1999-01-19 ES ES99900351T patent/ES2323199T3/es not_active Expired - Lifetime
- 1999-01-19 RU RU2000121989/14A patent/RU2204387C2/ru not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1050301A4 (de)	2004-11-17
CN1294511A (zh)	2001-05-09
CN1191062C (zh)	2005-03-02
JP4434486B2 (ja)	2010-03-17
EP1050301A1 (de)	2000-11-08
CA2319217A1 (en)	1999-07-22
IL137362A0 (en)	2001-07-24
ES2323199T3 (es)	2009-07-08
JPH11209277A (ja)	1999-08-03
NZ506408A (en)	2002-09-27
DE69940633D1 (de)	2009-05-07
CA2319217C (en)	2008-03-25
AU1891199A (en)	1999-08-02
KR20010034240A (ko)	2001-04-25
IL137362A (en)	2003-06-24
EP1050301B1 (de)	2009-03-25
KR100546450B1 (ko)	2006-01-26
PT1050301E (pt)	2009-06-16
WO1999036065A1 (en)	1999-07-22
BR9907099A (pt)	2001-09-04
RU2204387C2 (ru)	2003-05-20

Legal Events

Date

Code

Title

Description

2009-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1050301

Country of ref document: EP

2011-01-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
ATE426402T1 (de)	2009-04-15	Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l
BR9811453A (pt)	2000-09-12	Composição farmacêutica
ATE242633T1 (de)	2003-06-15	Dialkylfumarate zur behandlung von autoimmunerkrankungen
DE69828603D1 (de)	2005-02-17	Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von Autoimmunkrankheiten
EA200600076A1 (ru)	2006-08-25	Композиции и способы увеличения активности теломеразы
EP1562897A4 (de)	2007-06-27	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DK1131096T3 (da)	2010-05-17	Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
SG146691A1 (en)	2008-10-30	Methods of preparing and using stem cell compositions and kits comprising the same
PT812588E (pt)	2005-01-31	Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
BRPI9917007B8 (pt)	2021-05-25	azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso
BR0212078A (pt)	2004-09-28	Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
NO20022599D0 (no)	2002-05-31	Klorofyll- og bakterioklorofyllesteres, deres fremstilling og farmasöytiske sammensetninger som innbefatter slike
DE60012557D1 (de)	2004-09-02	Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
ATE314067T1 (de)	2006-01-15	Cannabinol-11-säurederivate als entzündungshemmer und analgetika
KR20040078663A (ko)	2004-09-10	난청의 치료 방법
WO2004031129A3 (en)	2004-07-15	Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2001038303A3 (fr)	2002-01-17	Analogues de la vitamine d
BR0010983A (pt)	2002-03-05	Preparações para a aplicação de agentes antiinflamatórios
TNSN01076A1 (fr)	2005-11-10	Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
AU2002333536A1 (en)	2003-03-24	Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
BR0011845A (pt)	2002-03-05	Complexo farmacêutico
ATE324898T1 (de)	2006-06-15	Behandlung von hiv infektionen
NO20022109D0 (no)	2002-05-02	Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon
JP4209488B2 (ja)	2009-01-14	皮膚創傷治療剤
ATE12649T1 (de)	1985-04-15	Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.